Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild

Amylyx Pharmaceuticals (AMLX) is transitioning from its ALS legacy to a late-stage endocrine company, with avexitide as its lead asset. AMLX's $250.8M cash runway extends into 2028, supporting LUCIDITY Phase 3 readout, regulatory submission, and potential 2027 launch without near-term financing risk. LUCIDITY's pivotal trial targets post-bariatric hypoglycemia, a large orphan market with no approved therapies; topline results expected late August or early September 2026.

Seeking Alpha • Aug 7, 2026

Amylyx Pharmaceuticals Q2 Earnings Call Highlights

Amylyx Pharmaceuticals NASDAQ: AMLX said its pivotal Phase III LUCIDITY trial of avexitide in post-bariatric hypoglycemia, or PBH, has completed final patient visits, with top-line data expected in late August or early September.

MarketBeat • Aug 6, 2026

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports Second Quarter 2026 Financial Results.

Business Wire • Aug 6, 2026

Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026.

Business Wire • Aug 3, 2026

Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

PRNewsWire • Jul 3, 2026

Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Data from First-in-Human, Dose-Ranging Phase 1 LUMINA Trial of AMX0114 in ALS at ENCALS 2026.

Business Wire • Jun 23, 2026

Amylyx Pharmaceuticals Eyes Q3 Phase 3 Avexitide Readout as PBH Launch Plans Take Shape

Amylyx Pharmaceuticals NASDAQ: AMLX Co-Chief Executive Officer Justin Klee said the company is preparing for a key Phase 3 readout for avexitide, its lead program for post-bariatric hypoglycemia, during an appearance at the Goldman Sachs Global Healthcare Conference.

MarketBeat • Jun 10, 2026

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 10, 2026

Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Securities of Amylyx Pharmaceuticals, Inc. – AMLX

BOSTON, June 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the District of Massachusetts has approved the following announcement of a proposed class action settlement that would benefit purchasers of publicly traded securities of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX): SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION To: All those who purchased or otherwise acquired Amylyx Pharmaceuticals, Inc. (“Amylyx”) securities between November 11, 2022, and November 8, 2023, inclusive (the “Class Period”), and who were allegedly damaged thereby (the “Settlement Class”). YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Massachusetts, that Plaintiff Oliver Shih, on behalf of himself and all members of the proposed Settlement Class, and Amylyx, Joshua B.

GlobeNewsWire • Jun 8, 2026